The DOI matches its Crossref record.
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
Abstract
Objective: Our objective was to assess the contribution of CYP2C9 genotype, age, body size, and vitamin K and lipid status to warfarin dose requirements. Methods: Patients with stable warfarin dose requirements and an international normalized ratio (INR) of the prothrombin time within the target range of 2.0 to 3.0 were recruited to the study. On arrival at the clinic in the morning, after an overnight fast, a blood sample was taken from each patient for CYP2C9 genotyping and for determination of venous INR and plasma vitamin K, R‐ and S‐warfarin, and triglyceride concentrations. Results: A total of 121 patients were recruited to the study. CYP2C9 genotyping showed that 74 patients were homozygous wild‐type (*1/*1), 30 were heterozygous *1/*2, and 15 were heterozygous *1/*3 genotype. One patient was found to have the genotype *2/*3, and another was found to have the genotype *3/*3. The mean warfarin daily dose requirement in milligrams fell from 4.06 ± 1.72 mg in homozygous wild‐type patients to 3.63 ± 1.78 mg for *1/*2‐positive patients and 2.70 ± 1.36 mg for *1/*3‐positive patients. The multiple linear regression model for warfarin dose indicated significant contributions from age (r = 0.41, P < .001), genotype (r = 0.24, P < .005), and age and genotype together (r = 0.45, P < .005). Although there were significant linear correlations between warfarin dose and body surface area (r = 0.21, P = .02), body weight (r = 0.25, P = .005), and plasma vitamin K concentration (r = 0.18, P < .05), none of these variables made a significant contribution to the regression model for warfarin dose. CYP2C9 genotype had a significant effect on S‐warfarin clearance (r = 0.34, P < .0001) but none on R‐warfarin clearance. Conclusion: This study showed that age and CYP2C9 polymorphism affect warfarin dose requirements in patients receiving long‐term therapy and having stable control of anticoagulation. It is anticipated that using dosing regimens modified to take into account the contribution of age and CYP2C9 genotype has the potential to improve the safety of warfarin therapy. Clinical Pharmacology & Therapeutics (2004) 75, 204–212; doi: 10.1016/j.clpt.2003.10.001
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K., & Kamali, F. (2005) · Blood · doi:10.1182/blood-2005-03-1108 · Cited by 947
Self-citationCommon VKORC1 and GGCX polymorphisms associated with warfarin dose
Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500313 · Cited by 468
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Corsonello, A., Pedone, C., & Incalzi, R. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416326 · Cited by 391
Takahashi, H., Wilkinson, G. R., Nutescu, E. A., Morita, T., Ritchie, M. D., Scordo, M. G., Pengo, V., Barban, M., Padrini, R., Ieiri, I., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000184955.08453.a8 · Cited by 376
Kubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006296058 · Cited by 334
Pharmacodynamics in Older Adults: A Review
Bowie, M. W., & Slattum, P. W. (2007) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2007.10.001 · Cited by 266
The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology
Schwartz, J. B. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100226 · Cited by 256
Pharmacokinetics in older persons
Cusack, B. J. (2004) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2004.12.005 · Cited by 253
Metadata
- Authors
- Kamali, F., Khan, T. I., King, B. P., Frearson, R., Kesteven, P., Wood, P., Daly, A. K., & Wynne, H.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2004-03
- Volume
- 75
- Issue
- 3
- Pages
- 204-212
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1967796257
- Cited by
- 218
- References
- 0
- FWCI
- 13.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.